Abstract
The metabolic signaling pathways that drive pathologic tissue inflammation and damage in humans with pulmonary tuberculosis (TB) are not well understood. Using combined methods in plasma high-resolution metabolomics, lipidomics and cytokine profiling from a multicohort study of humans with pulmonary TB disease, we discovered that IL-1β-mediated inflammatory signaling was closely associated with TCA cycle remodeling, characterized by accumulation of the pro-inflammatory metabolite succinate and decreased concentrations of the anti-inflammatory metabolite itaconate. This inflammatory metabolic response was particularly active in persons with multidrug-resistant (MDR)-TB that received 2 months of ineffective treatment and was only reversed after 1 year of appropriate anti-TB chemotherapy. Both succinate and IL-1β were significantly associated with proinflammatory lipid signaling, including increases in the products of phospholipase A2, increased arachidonic acid formation, and metabolism of arachidonic acid to proinflammatory eicosanoids. Together, these results indicate that decreased itaconate and accumulation of succinate and other TCA cycle intermediates are important drivers of IL-1β-mediated proinflammatory eicosanoid signaling in humans with pulmonary TB disease. Host-directed therapies that mitigate such metabolic reprograming have potential to limit pulmonary inflammation and tissue damage.
One Sentence Summary Remodeling of the tricarboxylic acid cycle, characterized by increases in the proinflammatory metabolite succinate and decreased itaconate, mediates proinflammatory eicosanoids signaling in humans with pulmonary tuberculosis through induction of IL-1β.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by grants from the NIH including R21 AI130918 (T.R.Z., N.R.G., J.C.M.B., D.P.J., R.R.K., H.M.B.), R01 AI087465 (N.R.G, N.S.S., J.C.M.B.), T32 AI074492 (J.M.C.), K23 AI144040 (J.M.C.), K24 AI114444 (N.R.G.), Georgia Clinical and Translational Science Alliance UL1 TR002378 (T.R.Z., H.M.B., J.M.C.), as well as grants from the Emory University Global Health Institute (T.R.Z., H.M.B., N.T., R.R.K.), and the Emory Medical Care Foundation (R.R.K., J.M.C., H.M.B., T.R.Z.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were approved by the Institutional Review Board (IRB) of Emory University (Atlanta, GA, USA), and by the individual IRBs associated with the original cohort studies: the Ethics Committee of the National Center for Tuberculosis and Lung Diseases of Georgia (Tbilisi, Georgia), the University of KwaZulu-Natal IRB (Durban, South Africa), and the Georgia Department of Public Health IRB (Atlanta, GA, USA), respectively, depending on the site of participant enrollment. All subjects provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All study data will be made available by the authors upon reasonable request.
